RRMS

Although the biological activity by which Copaxone (glatiramer) exerts its effects i multiple sclerosis (MS) patients is not fully understood, it is believed it can block the induction of autoimmune encephalomyelitis as observed in recent experiments with mice.  Research in animals and in vitro systems suggest that glatiramer acetate-specific suppressor…

New research work from GlaxoSmithKline presented by Daren Ausin, PhD, at the American Academy of Neurology’s 66th Annual Meeting has implications for individuals with relapsinig-remitting multiple sclerosis. The presentation detailed a study that used GlaxoSmithKline’s ofatumumab in 231 patients with relapse-remitting multiple sclerosis. Ofatumumab is an anti-B-cell antibody, and it…